Literature DB >> 19137117

Miniaturized GPCR signaling studies in 1536-well format.

S Shultz1, T Worzella, A Gallagher, J Shieh, S Goueli, K Hsiao, J Vidugiriene.   

Abstract

G protein-coupled receptors (GPCRs) are involved in various physiological processes, such as behavior changes, mood alteration, and regulation of immune-system activity. Thus, GPCRs are popular targets in drug screening, and a well-designed assay can speed up the discovery of novel drug candidates. The Promega cAMP-Glo Assay is a homogenous bioluminescent assay to monitor changes in intracellular cyclic adenosine monophosphate (cAMP) concentrations in response to the effect of an agonist, antagonist, or test compound on GPCRs. Together with the Labcyte Echo 555 acoustic liquid handler and the Deerac Fluidics Equator HTS reagent dispenser, this setup can screen compounds in 96-, 384-, and 1536-well formats for their effects on GPCRs. Here, we describe our optimization of the cAMP-Glo assay in 1536-well format, validate the pharmacology, and assess the assay robustness for HTS. We have successfully demonstrated the use of the assay in primary screening applications of known agonist and antagonist compounds, and confirmed the primary hits via secondary screening. Implementing a high-throughput miniaturized GPCR assay as demonstrated here allows effective screening for potential drug candidates.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19137117      PMCID: PMC2567138     

Source DB:  PubMed          Journal:  J Biomol Tech        ISSN: 1524-0215


  5 in total

1.  A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays.

Authors: 
Journal:  J Biomol Screen       Date:  1999

2.  The state of GPCR research in 2004.

Authors: 
Journal:  Nat Rev Drug Discov       Date:  2004-07       Impact factor: 84.694

3.  A bioluminescent-based, HTS-compatible assay to monitor G-protein-coupled receptor modulation of cellular cyclic AMP.

Authors:  Meera Kumar; Kevin Hsiao; Jolanta Vidugiriene; Said A Goueli
Journal:  Assay Drug Dev Technol       Date:  2007-04       Impact factor: 1.738

4.  Differential activation of adenylate cyclase and receptor internalization by novel dopamine D1 receptor agonists.

Authors:  Jessica P Ryman-Rasmussen; David E Nichols; Richard B Mailman
Journal:  Mol Pharmacol       Date:  2005-06-28       Impact factor: 4.436

5.  SCH 23390, a potential benzazepine antipsychotic with unique interactions on dopaminergic systems.

Authors:  L C Iorio; A Barnett; F H Leitz; V P Houser; C A Korduba
Journal:  J Pharmacol Exp Ther       Date:  1983-08       Impact factor: 4.030

  5 in total
  4 in total

Review 1.  Automating drug discovery.

Authors:  Gisbert Schneider
Journal:  Nat Rev Drug Discov       Date:  2017-12-15       Impact factor: 84.694

Review 2.  Biogenic amines and the control of neuromuscular signaling in schistosomes.

Authors:  Paula Ribeiro; Vandana Gupta; Nelly El-Sakkary
Journal:  Invert Neurosci       Date:  2012-04-18

3.  Effects of geissoschizine methyl ether, an indole alkaloid in Uncaria hook, a constituent of yokukansan, on human recombinant serotonin 7 receptor.

Authors:  Toshiyuki Ueki; Akinori Nishi; Sachiko Imamura; Hitomi Kanno; Kazushige Mizoguchi; Kyoji Sekiguchi; Yasushi Ikarashi; Yoshio Kase
Journal:  Cell Mol Neurobiol       Date:  2012-09-12       Impact factor: 5.046

Review 4.  Serotonin Receptor Binding Characteristics of Geissoschizine Methyl Ether, an Indole Alkaloid in Uncaria Hook.

Authors:  Yasushi Ikarashi; Kyoji Sekiguchi; Kazushige Mizoguchi
Journal:  Curr Med Chem       Date:  2018       Impact factor: 4.530

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.